Comment from Rare Disease Company Coalition

Summary: The Rare Disease Company Coalition (RDCC) supports the FDA's draft guidance on the Plausible Mechanism Framework, praising its efforts to address development challenges for small patient populations. They recommend that the framework be treated as an evidentiary approach within existing pathways, be applied more broadly based on scientific feasibility rather than narrow categories, and include more flexible CMC requirements and detailed case studies.